SELECT: Semaglutide reduces CV events in non-diabetic patients with overweight or obesitySemaglutide 2.4mg (Wegovy) reduces cardiovascular events in patients with overweight or obesity and pre-existing cardiovascular disease...
Semaglutide medication may benefit 93 million US adultsResearchers from the University of California, Irvine, have published a study that projects 93 million US adults that are overweight and...
Bariatric surgery reduces mortality in patients with obesity and sleep apnoeaBariatric surgery was associated with a 42% lower risk of major adverse cardiovascular events (MACE), including heart failure, heart...
Metabolic surgery results in fewer heart attacks, strokes and death among patients with diabetes Patients with diabetes and a history of metabolic surgery had significantly fewer heart attacks, strokes, hospitalisations and death,...
SOUL trial: Oral semaglutide demonstrates a 14% reduction in risk of major adverse CV events2 days ago